Cheng‐Ming Peng

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

1. Yen‐Yang Chen · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
2. Nai‐Jung Chiang · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
3. Jen‐Shi Chen · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
4. Wen‐Chi Chou · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
5. Tai‐Jan Chiu · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
6. Li‐Yuan Bai · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
7. Chung‐Pin Li · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
8. Shih‐Hung Yang · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
9. Yan‐Shen Shan · 8 shared papers, 2021–2024 · strength 1.06
   • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
   • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
   • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
10. Yung‐Yeh Su · 7 shared papers, 2021–2024 · strength 0.93
    • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
    • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
    • Paper The impact of starting dose with or without subsequent dose escalation of liposomal irinotecan on treatment outcomes in… PMID 36504882↗
11. Li‐Tzong Chen · 7 shared papers, 2021–2024 · strength 0.92
    • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
    • Paper Real-World Data Validation of NAPOLI-1 Nomogram for the Prediction of Overall Survival in Metastatic Pancreatic Cancer. DOI 10.3390/cancers15041008↗
    • Paper The impact of spleen volume on the survival of metastatic pancreatic adenocarcinoma patients receiving nanoliposomal ir… PMID 35530292↗
12. Brian Shiian Chen · 2 shared papers, 2022–2024 · strength 0.39
    • Paper The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.1007/s12029-023-00969-6↗
    • Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125↗
13. Cho‐Han Chiang · 2 shared papers, 2022–2024 · strength 0.39
    • Paper The Efficacy of Cationic Amphiphilic Antihistamines on Outcomes of Patients with Pancreatic Ductal Adenocarcinoma. DOI 10.1007/s12029-023-00969-6↗
    • Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125↗
14. Cheng‐Yu Tang · 1 shared paper, 2024 · strength 0.17
    • Paper Impact of previous S-1 treatment on efficacy of liposomal irinotecan plus 5-fluorouracil and leucovorin in patients wit… DOI 10.1016/j.pan.2024.03.014↗
15. Kevin Sheng‐Kai Ma · 1 shared paper, 2022 · strength 0.15
    • Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125↗
16. Yu‐Ze Luan · 1 shared paper, 2022 · strength 0.15
    • Paper The Efficacy of Liposomal Irinotecan Plus Fluorouracil/Leucovorin as First-Line Therapy in Patients With Locally Advanc… DOI 10.1097/mpa.0000000000002125↗
17. Hsiang‐Lin Lee · 1 shared paper, 2018 · strength 0.08
    • Paper Is mortality-to-incidence ratio associated with health disparity in pancreatic cancer? A cross-sectional database analy… DOI 10.1136/bmjopen-2017-020618↗
18. Wen‐Wei Sung · 1 shared paper, 2018 · strength 0.08
    • Paper Is mortality-to-incidence ratio associated with health disparity in pancreatic cancer? A cross-sectional database analy… DOI 10.1136/bmjopen-2017-020618↗
19. Ming‐Chang Tsai · 1 shared paper, 2018 · strength 0.08
    • Paper Is mortality-to-incidence ratio associated with health disparity in pancreatic cancer? A cross-sectional database analy… DOI 10.1136/bmjopen-2017-020618↗
20. Chi‐Chih Wang · 1 shared paper, 2018 · strength 0.08
    • Paper Is mortality-to-incidence ratio associated with health disparity in pancreatic cancer? A cross-sectional database analy… DOI 10.1136/bmjopen-2017-020618↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.